Efficacy of vibroacoustic therapy in treatment of pneumonia in children with bronchopulmonary dysplasia

Year & Volume - Issue: 
Authors: 
Madina Syzdykova, Marina Morenko, Madina Gatauova, Saule Zhumambayeva, Kseniya Shnaider
Heading: 
Article type: 
CID: 
e0307
PDF File: 
Abstract: 
Background — Advances in neonatal intensive care have resulted in high survival rates for infants born with extremely low birth weight. Accordingly, the treatment and rehabilitation of premature neonates with bronchopulmonary dysplasia (BPD) is indisputably an urgent problem. Objective — To evaluate the efficacy of vibroacoustic therapy in patients with BPD in the complex of therapeutic measures. Material and Methods — The study was a prospective, non-randomized open-label controlled clinical trial conducted in 2018-2020 in Astana, Kazakhstan. It included 69 children with BPD hospitalized with a concomitant diagnosis of pneumonia between the ages of 1 and 2 years. The study subjects were distributed among two groups: Group 1 (the main group, n=37) receiving vibroacoustic therapy with the VibroLung apparatus in combination with the main treatment and Group 2 (the control, n=32) receiving solely the main treatment. Results — The inclusion of the vibroacoustic method of treatment in the combination therapy of pneumonia in children with BPD resulted in early leveling of the following clinical symptoms: a reduction in the duration of the high fever by 1.18 days vs. the control group (p<0.05), relief of respiratory failure 1.4 days earlier vs. the control group (p<0.05) and a decrease in the duration of inpatient treatment by 2.9 days, compared with the control group (p<0.05). All of these implied the efficacy of this treatment method. Conclusion — Our results demonstrated that vibroacoustic therapy was a relevant addition to the treatment of pneumonia in children with BPD.
Cite as: 
Syzdykova M, Morenko M, Gatauova M, Zhumambayeva S, Shnaider K. Efficacy of vibroacoustic therapy in treatment of pneumonia in children with bronchopulmonary dysplasia. Russian Open Medical Journal 2023; 12: e0307.

Introduction

Preterm birth has become a global health problem worldwide due to its higher occurrence in recent decades [1, 2]. Over 70% of premature babies are born between 34 and 36 weeks of gestation [3]. At the same time, significant progress has been made in the tactics of nursing infants with very low birth weight (VLBW), including the introduction of surfactant replacement therapy, prenatal steroids and noninvasive ventilation methods, which can improve survival of preterm babies [4]. In Kazakhstan, concern about this problem increased in 2008 with the introduction of international criteria for live births and stillbirths recommended by the WHO [5]. From 2008 to 2016, 3,441,751 cases of live births were registered in Kazakhstan, including 204,613 preterm births, of which 82.5, 10.9% and 6.6% of neonates were born with low birth weight (LBW), VLBW and extremely low birth weight (ELBW), respectively [6].

Among the problem issues of preterm infants, respiratory pathology is the most frequent and adverse outcome in those with VLBW (<1500 g), with an overall incidence of about 30% [7]. Bronchopulmonary dysplasia (BPD) is a chronic inflammatory lung disease associated with delayed lung development and a need for supplemental oxygen. According to the National Institute of Child Health and Human Development (NICHD), USA, the 2001 clinical definition of BPD includes the need for supplemental oxygen at the post-conceptual age of 36 weeks [8].

Over the past decades, the incidence of BPD has increased significantly as a result of improved survival in case of extreme preterm birth, as a result of which neonates require mechanical ventilation. Data from large cohort studies (such as ELGAN, the Canadian Neonatal Network, Korean Neonatal Network, Vermont Oxford Network, and Swiss Neonatal Network), along with studies in China, Taiwan, and India, demonstrated a prevalence of BPD in the range of 11-50%. Such a wide range was due to differences in criteria for gestational age or birth weight for diagnosing BPD [9]. BPD is known to seriously compromise the wellbeing of extremely preterm neonates in both the short-term and long-term perspectives of their lives via higher risks of respiratory infections, asthma, and chronic obstructive pulmonary disease later in life [10-12]. Also, surviving children with BPD usually suffer from long-term impairment of lung function [13-15].

In addition to the above, newborns, especially preterm neonates, are among the most vulnerable age group in terms of morbidity and mortality from infections [16]. The immaturity of the innate immune system and the high need for invasive medical procedures for preterm birth make these children highly susceptible to various pathogens [17].

BPD has various long-term effects that were previously described in numerous studies, such as altered lung function, increased susceptibility to infections, and airway hyperresponsiveness. Children with such pathologies often undergo long and repeated hospitalizations. A persistent inflammatory process can lead to lifelong changes in lung function impairing their quality of life [18].

Despite severe lung dysfunction, some children with BPD achieve significant recovery in lung structure and function [9]. The future introduction of new methods of treatment and rehabilitation will contribute to the achievement of effective results. To date, most intervention studies did not detect a clear reduction in the incidence of BPD [19]. Therefore, research into new treatment methods of BPD is of paramount importance.

 

Material and Methods

This article presents the results of our prospective clinical controlled nonrandomized parallel-group study of preterm infants 1-2 years of age with a primary diagnosis of BPD and a concomitant diagnosis of pneumonia. All children were hospitalized in the Department of Early Childhood Pathology of the City Children’s Hospital in Astana, Kazakhstan, from April 2018 to December 2020. A total of 69 preterm babies were included in the study. They were distributed among two groups: Group 1 with children who received vibroacoustic therapy in combination with standard treatment for pneumonia and Group 2 with infants who received solely standard treatment. The characteristics of the study groups are presented in Table 1.

 

Table 1. Characteristics of the study groups

Characteristics

Group 1

Group 2

р

 n=37

 n=32

Gender:

Male

Female

 

20 (54.05%)

17 (45.95%)

 

17 (53.12%)

15 (46.8%)

 

0.558

Vaginal labor (%)

Cesarian section (%)

15 (40.6%)

22 (59.4%)

11 (34.4%)

21 (65.6%)

0.232

Birth weight, g

[IQR]

840.0

[745.0-940.0]

790.0

[680.0-900.0]

0.078

Birth length, cm

[IQR]

34.70

[31.0-35.0]

35.00

[33.5-38.0]

0.059

Gestational age

[IQR]

26.8

[26.0-27.1]

27.5

[27.1– 28.0]

0.361

Age, months

[IQR]

14.0

[13.0-16.0]

16.0

[14.0-19.0]

0.051

Apgar score

[IQR]

6[5.0-6.0]/

7[5.0-7.0]

6[5.0-6.5]/

7[7.0-7.5]

0.09

C-reactive protein content, g/L

[IQR]

5.8

[3.5-9.0]

7.1

[4.9-11.2]

0.063

 

All study subjects were monitored from the first day of hospitalization until discharge from the hospital. Upon admission to the hospital, they were offered vibroacoustic therapy as an additional method of therapy with an explanation of the scientific goal. Those whose parents signed the informed consent were in the main group, while those whose parents did not agree to vibroacoustic treatment were in the control group. Accordingly, patients were not randomized.

 

Inclusion and exclusion criteria

The criteria for inclusion in the study were as follows:

• Children 1-2 years of age with BPD who were hospitalized with a diagnosis of pneumonia.

The criteria for exclusion from the study were as follows:

• Infants with coronary artery disease or with signs of heart failure;

• Children with sepsis;

• Infants with epilepsy or convulsive syndrome.

 

Description of medical intervention

 Vibroacoustic therapy for children was carried out using the VibroLUNG apparatus with attachments suitable for children. To do so, before the session, the children were given inhalations of bronchodilators (Berodual, salbutamol) at the age-specific dosage. After that, we proceeded directly to the vibroacoustic therapy per se. The attachments were applied to the chest, bypassing the area of absolute cardiac dullness. The scheme of this therapy was selected individually depending on age and body type. The procedure was carried out 3-4 times a day.

The efficacy of vibroacoustic therapy was determined by assessing the state of respiratory failure syndrome and intoxication syndrome, and by the duration of inpatient treatment.

 

Statistical data processing

Statistical data processing was carried out using the Microsoft Office Home and Business 2013 x32/x64 Spreadsheet Application Package and IBM SPSS Statistics Base Campus Value Unit License v.24 (license agreement No. 20160805-1 of 30 August 30 2016 with Predictive Solutions CJSC). The nature of the data distribution was assessed using the Shapiro-Wilk test. Quantitative data were presented by central trends and scatter: median (Me) and interquartile range (Q1-Q3) in case of non-normal distribution of the data. The statistical hypothesis of equality of mean ranks was tested using the Mann-Whitney U test to compare two independent groups on one or more traits if at least one of the groups had data distribution other than normal or if the type of distributions was not checked. Relative indicators (shares, %) were used for qualitative characteristics. To assess the differences in relative values, we employed the analysis of contingency tables (χ2). Parameter values with p<0.05 were considered statistically significant. 

 

Results

Our results on the efficacy of vibroacoustic therapy are presented in Table 2. The combination therapy in patients with BPD and pneumonia yielded statistically significant differences in all investigated parameters.

 

Table 2 Clinical course of the disease in the study groups

Indicators

Group 1

Group 2

р

 n=37

 n=32

Duration of intercostal retraction, days [IQR]

4.4

[2.0-7.1]

6.3

[4.02-8.0]

0.013

Oxygen saturation upon admission to the hospital, % [IQR]

91

[89-93]

90

[88-93]

0.537

Day of hospitalization when oxygen saturation returned to normal (>95), [IQR]

7.9

[5.0-9.1]

9.4

[7.5-10.0]

0.009

Duration of fever, days [IQR]

3

[1.6-4.4]

4.2

[2.8-5.6]

0.01

Duration of inpatient treatment, days [IQR]

8.9

[6.0-12.4]

11.8

[7.1-16.0]

0.008

 

 When examining respiratory failure due to BPD in the study groups, we discovered that most children (59.5%) of the main group had grade 2 respiratory failure, while grade 1 and grade 3 were observed in 37.8% and 2.7% of cases, respectively. In the control group, 54.7% of study subjects exhibited grade 2 respiratory failure, whereas grade 1 and 3 were observed in 42.9% and 2.4% of cases, correspondingly. We detected no statistically significant difference between the study groups (p=0.07). However, the duration of the respiratory failure syndrome (oxygen saturation, intercostal retraction) in the studied groups was statistically significantly different (p<0.05), as seen in Table 2. For this comparison, we used the Mann-Whitney U test for independent samples.

Analysis of the fever response in the studied patients showed the following trend: the average measured temperature in the main group was 37.2±0.9 ºС vs. 37.2±1.01 ºС in the comparison group, and the duration of the fever response was 3.02±1.6 d. Hence, an assessment of the fever response in the groups did not reveal a statistically significant difference between them (p=0.103), while the duration of fever was statistically significantly different (p=0.01, Table 2).

In addition to clinical data, we also analyzed the duration of inpatient treatment, which may indirectly indicate the efficacy of combination therapy. In the control group, the duration of inpatient treatment was, on average, 2.9 d shorter (p=0.008).

Therefore, the inclusion of the vibroacoustic treatment method in the combination therapy of pneumonia in children with BPD resulted in early leveling of the following clinical symptoms: a reduction in the duration of the fever response by 1.18 d vs. the control group (p=0.01), relief of respiratory failure by 1.4 d earlier vs. the control group (p=0.009) and a shorter duration of inpatient treatment by 2.9 d vs. the control group (p=0.008). All of these results confirmed the efficacy of this treatment method.

 

Discussion

Previous studies demonstrated that gestational age was not always a risk factor for hospital readmission. However, the developed BPD contributed more to the risk of rehospitalization of extremely preterm infants. The association between BPD and readmission was demonstrated in many studies [20-22]. Preterm neonates, especially those with BPD, exhibited varying degrees of lung damage with increased susceptibility to infection and bronchospasm [23]. Reducing the duration of inpatient treatment is one of the priorities in the management of premature babies. Early combined rehabilitation intervention can improve the degree of dyspnea in this category of patients [24].

Our study on the use of vibroacoustic therapy for infants with BPD demonstrated high efficacy. It is the first of the kind in this field. The inclusion of such therapy for patients with BPD made it possible to quickly stop clinical symptoms and, as a result, reduce the length of their hospital stay. To assess the efficacy of vibroacoustic therapy were examined the duration of the respiratory failure syndrome, intoxication syndrome and inpatient treatment. The first indicator differed significantly between the groups (dyspnea lasted 1.4 d less in the group with vibroacoustic therapy, p=0.009).

The duration of the fever response also had a statistically significant difference (p=0.01). In the main group, fever persisted 1.2 d less than in the control group. The duration of inpatient treatment declined in the main group vs. the control group by 3.1 d (p=0.008). The obtained data on the use of the combination therapy of pneumonia in patients with BPD allowed assessing the efficacy of vibroacoustic therapy and the expansion of the therapeutic possibilities of using this method of treatment.

Our study had certain limitations. This was a single-center trial with a small sample size without randomization, in which only relevant indicators were assessed during hospitalization. To further confirm our short-term results, we need to increase the sample size.

 

Conclusion

Experts and caregivers of BPD look forward to advances in the treatment of this disease, for which there exist many evidence-based options for the prevention and symptom relief but no definitive treatment recommendations to date [25]. It is now known that children who experienced BPD suffer from decreased lung function in adulthood and, as a result, are at higher risk of developing chronic obstructive pulmonary disease in the future [26-28]. Based on our results, we can conclude that the inclusion of vibroacoustic therapy in the complex of measures for long-term management of BPD patients with the development of acute respiratory pathology can be an effective measure to reduce the inpatient treatment time. Effective and rapid treatment of recurrent conditions in BPD will improve the quality of life of these patients.

 

Conflict of interest

The authors declare no conflicts of interest.

 

Ethical approval

This study was reviewed by the Bioethics Committee at Astana Medical University. Excerpts from the Protocol No. 1 of 15 March 15 v2018 are attached. The authors complied with the ethical principles of the Declaration of Helsinki and World Medical Association. The informed consent was signed by all patients prior to their participation in the study.

 

Funding

This research received no external funding.

References: 
  1. Barros FC, Victora CG, Barros AJ, Santos IS, Albernaz E, Matijasevich A, et al. The challenge of reducing neonatal mortality in middle-income countries: Findings from three Brazilian birth cohorts in 1982, 1993, and 2004. Lancet 2005; 365(9462): 847-854. https://doi.org/10.1016/S0140-6736(05)71042-4.
  2. Buitendijk S, Zeitlin J, Cuttini M, Langhoff-Roos J, Bottu J. Indicators of fetal and infant health outcomes. Eur J Obstet Gynecol Reprod Biol 2003; 111 Suppl 1: S66-S77. https://doi.org/10.1016/j.ejogrb.2003.09.007.
  3. Davidoff MJ, Dias T, Damus K, Russell R, Bettegowda VR, Dolan S, et al. Changes in the gestational age distribution among U.S. singleton births: Impact on rates of late preterm birth, 1992 to 2002. Semin Perinatol 2006; 30(1): 8-15. https://doi.org/10.1053/j.semperi.2006.01.009.
  4. Abman SH, Bancalari E, Jobe A. The evolution of bronchopulmonary dysplasia after 50 years. Am J Respir Crit Care Med 2017; 195(4): 421-424. https://doi.org/10.1164/rccm.201611-2386ed.
  5. On approval of the Program to reduce maternal and child mortality in the Republic of Kazakhstan for 2008-2010 Decree of the Government of the Republic of Kazakhstan dated December 28, 2007 N 1325. https://adilet.zan.kz/rus/docs/P070001325_.
  6. Syzdykova M. Features of the Course of Community-Acquired Pneumonia in Premature Infants of Their First Year of Life: MSc thesis. Astana. 2017: 12-16. https://elib.amu.kz/kz/lib/document/KNIGA/E7269041-F5C2-4F69-A628-FD0B9792D6BA.
  7. Lignelli E, Palumbo F, Myti D, Morty RE. Recent advances in our understanding of the mechanisms of lung alveolarization and bronchopulmonary dysplasia. Am J Physiol Lung Cell Mol Physiol 2019; 317(6): L832-L887. https://doi.org/10.1152/ajplung.00369.2019.
  8. Jobe AH, Bancalari E. Bronchopulmonary dysplasia. Am J Respir Crit Care Med 2001; 163(7): 1723-1729. https://doi.org/10.1164/ajrccm.163.7.2011060.
  9. Thébaud B, Goss KN, Laughon M, Whitsett JA, Abman SH, Steinhorn RH, et al. Bronchopulmonary dysplasia. Nat Rev Dis Primers 2019; 5: 78. https://doi.org/10.1038/s41572-019-0127-7.
  10. Islam JY, Keller RL, Aschner JL, Hartert TV, Moore PE. Understanding the short- and long-term respiratory outcomes of prematurity and bronchopulmonary dysplasia. Am J Respir Crit Care Med 2015; 192(2): 134-156. https://doi.org/10.1164/rccm.201412-2142pp.
  11. Silva LV, Araujo LB, Azevedo V. Assessment of the neuropsychomotor development in the first year of life of premature infants with and without bronchopulmonary dysplasia. Rev Bras Ter Intensiva 2018; 30(2): 174-180. https://doi.org/10.5935/0103-507x.20180023.
  12. Pérez Tarazona S, Solano Galán P, Bartoll Alguacil E, Alfonso Diego J. Bronchopulmonary dysplasia as a risk factor for asthma in school children and adolescents: A systematic review. Allergol Immunopathol (Madr) 2018; 46(1): 87-98. https://doi.org/10.1016/j.aller.2017.02.004.
  13. Balinotti JE, Chakr VC, Tiller C, Kimmel R, Coates C, Kisling J, et al. Growth of lung parenchyma in infants and toddlers with chronic lung disease of infancy. Am J Respir Crit Care Med 2010; 181(10): 1093-1097. https://doi.org/10.1164/rccm.200908-1190oc.
  14. Vardar-Yagli N, Inal-Ince D, Saglam M, Arikan H, Savci S, Calik-Kutukcu E, et al. Pulmonary and extrapulmonary features in bronchopulmonary dysplasia: A comparison with healthy children. J Phys Ther Sci 2015; 27(6): 1761-1765. https://doi.org/10.1589/jpts.27.1761.
  15. Vom Hove M, Prenzel F, Uhlig HH, Robel-Tillig E. Pulmonary outcome in former preterm, very low birth weight children with bronchopulmonary dysplasia: A case-control follow-up at school age. J Pediatr 2014; 164(1): 40-45.e4. https://doi.org/10.1016/j.jpeds.2013.07.045.
  16. World Health Organization. World Health Statistics: 2010. Geneva. 2010; 177 р. https://www.who.int/publications/i/item/9789241563987.
  17. Siegrist CA, Aspinall R. B-cell responses to vaccination at the extremes of age. Nat Rev Immunol 2009; 9(3): 185-194. https://doi.org/10.1038/nri2508.
  18. McEvoy CT, Jain L, Schmidt B, Abman S, Bancalari E, Aschner JL. Bronchopulmonary dysplasia: NHLBI workshop on the primary prevention of chronic lung diseases. Ann Am Thorac Soc 2014; 11 Suppl 3(Suppl 3): S146-S153. https://doi.org/10.1513/annalsats.201312-424ld.
  19. Doyle LW, Halliday HL, Ehrenkranz RA, Davis PG, Sinclair JC. An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: Effect modification by risk of bronchopulmonary dysplasia. J Pediatr 2014; 165(6): 1258-1260. https://doi.org/10.1016/j.jpeds.2014.07.049.
  20. Liu S, Wen SW, McMillan D, Trouton K, Fowler D, McCourt C. Increased neonatal readmission rate associated with decreased length of hospital stay at birth in Canada. Can J Public Health 2000; 91(1): 46-50. https://doi.org/10.1007/bf03404253.
  21. Ralser E, Mueller W, Haberland C, Fink FM, Gutenberger KH, Strobl R, et al. Rehospitalization in the first 2 years of life in children born preterm. Acta Paediatr 2012; 101(1): e1-e5. https://doi.org/10.1111/j.1651-2227.2011.02404.x.
  22. Mowitz ME, Dukhovny D, Zupancic JAF. The cost of necrotizing enterocolitis in premature infants. Semin Fetal Neonatal Med 2018; 23(6): 416-419. https://doi.org/10.1016/j.siny.2018.08.004.
  23. Grégoire MC, Lefebvre F, Glorieux J. Health and developmental outcomes at 18 months in very preterm infants with bronchopulmonary dysplasia. Pediatrics 1998; 101(5): 856-860. https://doi.org/10.1542/peds.101.5.856.
  24. Liu Y, Li ZF, Zhong YH, Zhao ZH, Deng WX, Chen LL, et al. Early combined rehabilitation intervention to improve the short-term prognosis of premature infants. BMC Pediatr 2021; 21(1): 269. https://doi.org/10.1186/s12887-021-02727-8.
  25. Bonadies L, Zaramella P, Porzionato A, Perilongo G, Muraca M, Baraldi E. Present and future of bronchopulmonary dysplasia. J Clin Med 2020; 9(5): 1539. https://doi.org/10.3390/jcm9051539.
  26. Baraldi E., Filippone M. Chronic lung disease after premature birth. N Engl J Med 2007; 357(19): 1946-1955. https://doi.org/10.1056/nejmra067279.
  27. Martinez FD. Early-life origins of chronic obstructive pulmonary disease. N Engl J Med 2016; 375: 871-878. https://doi.org/10.1056/nejmra1603287.
  28. Vollsæter M, Clemm HH, Satrell E, Eide GE, Røksund OD, Markestad T, et al. Adult respiratory outcomes of extreme preterm birth a regional cohort study. Ann Am Thorac Soc 2015; 12(3): 313-322. https://doi.org/10.1513/annalsats.201406-285oc.
About the Authors: 

Madina Syzdykova – PhD, Assistant professor, Department of Children’s Diseases with Courses in Allergology, Hematology and Endocrinology, Astana Medical University, Nur-Sultan, Kazakhstan. https://orcid.org/0000-0001-6863-303X
Marina Morenko – MD, DSc, Professor, Head of Department of Children’s Diseases with Courses in Allergology, Hematology and Endocrinology, Astana Medical University, Nur-Sultan, Kazakhstan. https://orcid.org/0000-0001-9553-3560
Madina Gatauova – MD, PhD, Assistant professor, Department of Children's Diseases with Courses in Allergology, Hematology and Endocrinology, Astana Medical University, Nur-Sultan, Kazakhstan. https://orcid.org/0000-0002-6570-192X
Saule Zhumambayeva – PhD, Assistant professor, Department of Children’s Diseases with Courses in Allergology, Hematology and Endocrinology, Astana Medical University, Nur-Sultan, Kazakhstan. https://orcid.org/0000-0002-9298-0055
Kseniya Shnaider – PhD, Assistant professor, Department of Children’s Diseases with Courses in Allergology, Hematology and Endocrinology, Astana Medical University, Nur-Sultan. Kazakhstan. https://orcid.org/0000-0002-4919-1878

Received 4 April 2023, Revised 20 June 2023, Accepted 22 August 2023 
© 2023, Russian Open Medical Journal 
Correspondence to Madina Syzdykova. E-mail: smm170782@gmail.com.

DOI: 
10.15275/rusomj.2023.0307

hcs777 hcs777 hcs777